Cargando…

Modelling metabolic diseases and drug response using stem cells and organoids

Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenxiang, Lazar, Mitchell A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449917/
https://www.ncbi.nlm.nih.gov/pubmed/36071283
http://dx.doi.org/10.1038/s41574-022-00733-z
_version_ 1784784406226927616
author Hu, Wenxiang
Lazar, Mitchell A.
author_facet Hu, Wenxiang
Lazar, Mitchell A.
author_sort Hu, Wenxiang
collection PubMed
description Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases.
format Online
Article
Text
id pubmed-9449917
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94499172022-09-07 Modelling metabolic diseases and drug response using stem cells and organoids Hu, Wenxiang Lazar, Mitchell A. Nat Rev Endocrinol Review Article Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to understand the underlying mechanisms and develop rational treatments are limited by the lack of appropriate human model systems. Notably, advances in stem cell and organoid technology allow the generation of cellular models that replicate the histological, molecular and physiological properties of human organs. Combined with marked improvements in gene editing tools, human stem cells and organoids provide unprecedented systems for studying mechanisms of metabolic diseases. Here, we review progress made over the past decade in the generation and use of stem cell-derived metabolic cell types and organoids in metabolic disease research, especially obesity and liver diseases. In particular, we discuss the limitations of animal models and the advantages of stem cells and organoids, including their application to metabolic diseases. We also discuss mechanisms of drug action, understanding the efficacy and toxicity of existing therapies, screening for new treatments and pursuing personalized therapies. We highlight the potential of combining stem cell-derived organoids with gene editing and functional genomics to revolutionize the approach to finding treatments for metabolic diseases. Nature Publishing Group UK 2022-09-07 2022 /pmc/articles/PMC9449917/ /pubmed/36071283 http://dx.doi.org/10.1038/s41574-022-00733-z Text en © Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Hu, Wenxiang
Lazar, Mitchell A.
Modelling metabolic diseases and drug response using stem cells and organoids
title Modelling metabolic diseases and drug response using stem cells and organoids
title_full Modelling metabolic diseases and drug response using stem cells and organoids
title_fullStr Modelling metabolic diseases and drug response using stem cells and organoids
title_full_unstemmed Modelling metabolic diseases and drug response using stem cells and organoids
title_short Modelling metabolic diseases and drug response using stem cells and organoids
title_sort modelling metabolic diseases and drug response using stem cells and organoids
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449917/
https://www.ncbi.nlm.nih.gov/pubmed/36071283
http://dx.doi.org/10.1038/s41574-022-00733-z
work_keys_str_mv AT huwenxiang modellingmetabolicdiseasesanddrugresponseusingstemcellsandorganoids
AT lazarmitchella modellingmetabolicdiseasesanddrugresponseusingstemcellsandorganoids